Incyte Stock Reverses, Though Questions Face Its Key Growth Product
Technology Incyte Wavers As Growth Questions Plague Its Up-And-Coming Drug Licensing ALLISON GATLIN Updated 04:16 PM ET 04/28/2026 Incyte (INCY) stock wavered Tuesday, but closed in the green, as growth questions surrounding its eczema cream, Opzelura, plagued its first-quarter beat. Opzelura is one of Incyte's key growth drivers. But first-quarter sales came in at $143 million, missing forecasts for $149 million, RBC Capital Markets analyst Brian Abrahams said in a report to clients.
- ▪Technology Incyte Wavers As Growth Questions Plague Its Up-And-Coming Drug Licensing ALLISON GATLIN Updated 04:16 PM ET 04/28/2026 Incyte (INCY) stock wavered Tuesday, but closed in the green, as growth questions surrounding its eczema crea
- ▪Opzelura is one of Incyte's key growth drivers.
- ▪But first-quarter sales came in at $143 million, missing forecasts for $149 million, RBC Capital Markets analyst Brian Abrahams said in a report to clients.
Opening excerpt (first ~120 words) tap to expand
Technology Incyte Wavers As Growth Questions Plague Its Up-And-Coming Drug Licensing ALLISON GATLIN Updated 04:16 PM ET 04/28/2026 Incyte (INCY) stock wavered Tuesday, but closed in the green, as growth questions surrounding its eczema cream, Opzelura, plagued its first-quarter beat. Opzelura is one of Incyte's key growth drivers. But first-quarter sales came in at $143 million, missing forecasts for $149 million, RBC Capital Markets analyst Brian Abrahams said in a report to clients.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Investor's Business Daily.
Discussion
0 commentsMore from Investor's Business Daily
